Re: Zenith-Oncology Pipeline
in response to
by
posted on
Mar 23, 2021 07:54AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
As there currently isn't any real market for Zenith other than the OTC I would say that the value is what someone would pay for a LARGE # of shares, not the paltry few thousand that trade daily. And as there is no market, there is no large scale value for anyone hoping to exit anytime soon.
Not suggesting that Zenith doesn't have value, it is just impossible to unlock that value at the moment. At this rate it WILL be my estate settling the dispostion of the shares. Based on average life expectancy I have used up one third of the time I have left waiting. 10 years in and hopefully at least 20 years (of life expectancy not share ownership) to go.
Long and no longer very strong.